Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02) Iza-bren, Osimertinib, Pemetrexed - Non-Small Cell Lung Cancer Phase 3 Recruiting Bristol-Myers Squibb 850 2026-09-08 2026-10-26 A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04) BL-B01D1, PD-1 monoclonal antibody, Nab-paclitaxel - Triple-Negative Breast Cancer (TNBC) Phase 3 Recruiting Sichuan Baili Pharmaceutical Co., Ltd. 436 2026-09-02 2026-09-30 A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma BL-B01D1, PD-1 monoclonal antibody, Gemcitabine - Nasopharyngeal Carcinoma (NPC) Phase 2 Not yet recruiting Sichuan Baili Pharmaceutical Co., Ltd. 60 2026-09-01 2026-09-16 A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer BL-B01D1, Glecirasib - Non-small Cell Lung Cancer Phase 2 Not yet recruiting Sichuan Baili Pharmaceutical Co., Ltd. 36 2026-09-01 2026-09-18 A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02) BL-B01D1, PD-1 monoclonal antibody, cisplatin - Nasopharyngeal Carcinoma (NPC) Phase 3 Not yet recruiting Sichuan Baili Pharmaceutical Co., Ltd. 404 2026-09-01 2026-09-15 A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer BL-B01D1, Abiraterone, Olaparib - Castration-resistant Prostate Cancer Phase 2 / Phase 3 Not yet recruiting Sichuan Baili Pharmaceutical Co., Ltd. 180 2026-09-01 2026-07-23 A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08) BL-B01D1, Osimertinib - Non-small Cell Lung Cancer Stage III Phase 3 Recruiting Sichuan Baili Pharmaceutical Co., Ltd. 418 2026-08-28 2026-09-10 A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05) BL-B01D1, PD-1/VEGF bispecific antibody, Paclitaxel - Squamous Non-small-cell Lung Cancer Phase 2 / Phase 3 Not yet recruiting Sichuan Baili Pharmaceutical Co., Ltd. 200 2026-08-01 2026-08-26 A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06) BL-B01D1, PD-1/VEGF Bispecific Antibody, Tislelizumab - Non-squamous Non-small Cell Lung Cancer Phase 2 / Phase 3 Not yet recruiting Sichuan Baili Pharmaceutical Co., Ltd. 120 2026-08-01 2026-08-26 A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09) BL-B01D1, Osimertinib, Carboplatin - Non-small Cell Lung Cancer Phase 2 / Phase 3 Recruiting Sichuan Baili Pharmaceutical Co., Ltd. 90 2026-07-24 2026-08-03 A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03) BL-B01D1, Albumin-Bound Paclitaxel, Paclitaxel - Breast Cancer Phase 3 Recruiting Sichuan Baili Pharmaceutical Co., Ltd. 446 2026-07-06 2026-07-23 A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01) BL-B01D1, Oxaliplatin, Calcium levofolinate - Biliary Tract Cancer Phase 3 Recruiting Sichuan Baili Pharmaceutical Co., Ltd. 538 2026-06-29 2026-07-24 A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07) BL-B01D1, Tislelizumab, Carboplatin - Extensive-stage Small-cell Lung Cancer Phase 3 Recruiting Sichuan Baili Pharmaceutical Co., Ltd. 562 2026-06-15 2026-07-27 A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02) BL-B01D1, Tislelizumab, 5-Fluorouracil - Esophageal Squamous Cell Carcinoma Phase 2 / Phase 3 Recruiting Sichuan Baili Pharmaceutical Co., Ltd. 90 2026-06-09 2026-07-16 Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial Adagrasib, Iza-bren - Non-small Cell Lung Cancer Phase 1 Recruiting M.D. Anderson Cancer Center 18 2026-05-15 2026-08-11 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) Iza-bren, Carboplatin, Cisplatin - Non-Small Cell Lung Cancer Phase 2 / Phase 3 Recruiting Bristol-Myers Squibb 500 2025-11-05 2026-10-09 Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy Iza-bren, Cisplatin, Gemcitabine - Urothelial Cancer Phase 2 / Phase 3 Recruiting Bristol-Myers Squibb 470 2025-09-30 2026-07-29 A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) Iza-bren, Nab-paclitaxel, Paclitaxel - Breast Neoplasms Phase 2 / Phase 3 Recruiting Bristol-Myers Squibb 600 2025-09-11 2026-08-10 A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9) BMS-986504, Izalontamab Brengitecan - Carcinoma, Non-Small-Cell Lung Phase 2 Recruiting Bristol-Myers Squibb 182 2025-09-09 2026-09-18 A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer BL-B01D1, Pembrolizumab, Bevacizumab - Cervical Cancer, Endometrial Cancer Phase 2 Recruiting Sichuan Baili Pharmaceutical Co., Ltd. 96 2025-08-21 2026-01-21